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and in the Schuss position at entry and after a 2-year follow-up. 
The minimum interbone distance (MID), the surface area nd the 
mean joint space width were measured using a graduated eye- 
piece and/or an image analysis system, lntraobserver epro- 
ducibility was determined by the intraclass coefficient of correla- 
tion (ICC). Sensitivity to change was analyzed by the standard- 
ized response mean (SRM). 
Results: The various methods displayed a good reproducibility, 
the best one being obtained with the computerized measurement 
of MID (ICC=0.98). The latter also demonstrated a slightly better 
sensitivity to change. Progression of joint space narrowing was 
larger with the schuss view than with the standard view (0.24 and 
0.17 mm, respectively for MID), the SRM being 0.48 for the for- 
mer and 0.23 for the latter. Progression of joint space narrowing 
was also highly dependent upon the quality of the view (horizon- 
tality of the tibial plateau) and the superimposability of the con- 
secutive films. 
Conclusion: measurement of the femorotibial space width is an 
easy task. However, assessment of progression of narrowing of 
the joint space largely varies according to the degree of knee flex- 
ion as well as to the quality and the superimposability of the 
femorotibial joint images. 
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PROPORTIONAL PREVALENCE OF OSTEOARTHRITIS OF 
THE KNEE IN A TROPICAL TEACHING HOSPITAL 
T.O. Alonge, S.O. Ogunlade 
Department of Surgery, College of Medicine, University of 
Ibadan, Ibadan, Nigeria 
Aim: The aim of this study was to ascertain the prevalence or 
otherwise of osteoarthritis in a teaching hospital of a developing 
country. 
Methods: All new referrals to the Orthopaedic Surgical 
Outpatient clinic of the University College Hospital (UCH), Ibadan 
in Nigeria between April 1997 and March 1998 were entered into 
a register. The various lesions were grouped into one of five bone 
and joint disease (BJD) class. BJD-Class 1 (Congenital), Class 2 
(Traumatic), Class 3 (Infective/Inflammatory), Class 4 
(Degenerative) and Class 5(Neoplastic). At the end of the study 
period of 24 months the proportional prevalence of the diseases 
were estimated. 
Results: Of the degenerative lesions (Class 4) osteoarthritis of 
the knee was the commonest accounting for 32.5% of all class 4 
diseases and 7% of the overall referrals. There was also a pre- 
dominant female affectation with a male to female ratio of 1:10.5. 
The average age of the patient was 57 years. 
Conclusions: Ibadan, one of the largest cities in Nigeria has a 
population of 2 million people. U.C.H Ibadan is the premier and 
largest tertiary health institution in Nigeria and offers pecialist 
care. The proportional prevalence reported in this study appar- 
ently represents an underestimation of these diseases since most 
of the patients seek medical attention at the primary and sec- 
ondary health care centers. 
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_ Dept of Epidemiology and Public Health, University of Liege, 
Liege, Belgium; 
_ Rotta Research Laboratories, Monza, Italy 
Objectives: The aim of the present study was to take advantage 
of a cohort of subjects with mild to moderate knee OA observed 
as the placebo-arm of a three-year prospective, double-blind, 
randomized trial on the effect of giucosamine sulfate to assess 
the impact of radiographic severity and progression on pain and 
disability. 
Material and Method: 212 subjects over 50 years presenting 
with primary knee OA of the medial femoro-tibial compartment on 
a anteroposterior radiograph of the knee. Measurements of mean 
joint space width (JSW) (computer-assisted after image digitali- 
zation) and the narrowest join space (NJS) point (graduated mag- 
nifying lens) and assessment of symptoms by the WOMAC ques- 
tionnaire were performed at baseline and after three years. 
Results: At baseline, in the overall population (n = 212), JSW and 
NJS were not significantly correlated with the scores recorded for 
the WOMAC global index or its pain, stiffness or function sub- 
scales. In the patients from the placebo group, there were no sta- 
tistically significant correlation between baseline values of JSW 
and NJS and the changes observed, at three years, in symptoms. 
A statistically significant correlation was observed between the 
joint space narrowing over three years and the changes observed 
in the pain subscale of the WOMAC during the same period (r = - 
0.29, p=0.0017 and r = -0.24, p = 0.044 for JSW and NJS, 
respectively). Furthermore, such correlation with radiological 
changes was not observed for the global WOMAC, the stiffness 
or function subscales. The three-year changes in the global 
WOMAC index in patients within the lowest and the highest quar- 
tiles of mean joint space width at baseline showed in both cases, 
a statistically (p < 0.05) significant favorable difference between 
patients treated with glucosamine sulfate and those having 
received placebo. 
Conclusion: The results suggest the absence of correlation 
between baseline joint space width of the medial compartment of 
the femoro-tibial joint and the clinical impact or progression of the 
disease. Radiographic and clinical progressions of the disease 
are significantly associated but the clinical relevance of the asso- 
ciation is questionable. Glucosamine sulfate provides long-term 
relief of symptoms independently of baseline joint space width in 
patients with mild to moderate osteoarthritis of the knee. 
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TREATMENT OF OSTEOARTHRITIS IN THE ARTHRITIS 
CLINIC OF THE PHILIPPINE GENERAL HOSPITAL: 
A PRELIMINARY REPORT 
EG Penserga, IC Rivera, AL Lucero, Jr 
University of the Philippines General Hospital, Malate, MM 
Introduction: Osteoarthritis (OA) is a leading cause of pain and 
debility worldwide. The prevalence of OA is 33% in western 
countries. In the Philippines, the prevalence is 16.3%_and the 
point prevalence of OA is 4.1% in this relatively oung population. 
Pain and disability are the major clinical presentations of OA. 
Treatment of OA for many years has centered on the use of non- 
steroidal anti-inflammatory drugs (NSAIDs). In 1995, the ACR pro- 
posed a treatment guideline which was subsequently updated in 
2000. 
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Objectives: This paper will compare the treatment of CA in the 
Philippine General Hoapital, Outpatient Arthritis 'Clinic before and 
after the 1995 publication of the Guidelines for Treatment of CA 
of the hips, knees and hands. 
Methods: This is a descriptive retrospective study of patients 
diagnosed to have osteoarthritis based on ACR criteria. It will 
compare management of patients seen in 1994 and 1999, using 
a data collection form. 
Results: 
Treatment 1994 1999 
n = 33 n=62 
(%) (%) 
Non-Pharmacological 
Education 10 (30) 50 (81) 
Weight loss 4(t2) 11 (18) 
OT 1 (3) 4(6) 
PT 17 (52) 3 (52) 
Pharmacological 
Paracetamol 11 (33) 32 (52) 
Tramadol 1 (3) 6 (10) 
Meperidine 0 0 
Codeine 0 0 
NSAIDs 30(91) 46(74) 
Topical 6(18) 2(3) 
IA Steroids 0 9(15) 
Glucosamine 0 35(56) 
HMP 33 0 7(11) 
Other Drugs 0 0 
Surgical 
Osteotomy 0 1 (2) 
Joint Replacement 0 0 
Others 0 0 
*OT occupational therapy 
*PT physical therapy 
*IA = intraarticular 
Conclusion: This is a preliminary data and so far, the trend has 
shown increasing use of the analgesics and non-pharmacologic 
treatment of osteoarthritis after issuance of the treatment guide- 
lines. NSAIDs still is the most common drug intervention used. 
Our low utilization of health support systems and psychological 
support may stem for the extended family set-up that most 
Filipinos have. 
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EXPERIMENTAL MODEL OF OSTEOARTHRITIS 
AND ITS THERAPY WITH THE TINCTURE OF 
FILIPENDULA ULMARJS (L) MAXIM 
L Leonaviciene, A Keturkiene, D Vaitkiene, R Bradunaite 
Institute of Experimental and Clinical Institute, Vilnius, Lithuania 
Aim: The aim of this study was to investigate antiarthritic effect of 
tincture from Filipendula ulmaria (L.) Maxim (FU) by using an 
experimental model of osteoarthritis (CA) in rats. 
Methods: CA was reproduced by combination of both biochem- 
ical and surgical methods. One day before the transection of 
anterior cruciate ligaments 60 rats received a single intra-articu- 
lar injection of 20 ;LI 2% dextran sulphate solution. The animals 
with CA were distributed into controls and treated groups; 10 ani- 
mals served as non-operated control. FU tincture was produced 
from wild plants growing in Lithuania (A.Keturkiene t al. Apply for 
patent N 2001 036). Three different doses of FU (4, 8 and 17 
mg/kg -1 calculated to dry weight of tincture) were given daily as 
intragastnc injections. 3 control CA groups received: acetylsali- 
cylicum acid (ASA) at a dose of 21 mg/kg -1 for salicylic com- 
pounds, ethanol 8 mg/kg -1 -- for tincture solvent, and water. The 
treatment was started one week postoperatively and lasted for 
20 days. Pathomorphological changes in joints, liver and 
stomach tissue were investigated histologically at the end of the 
experiment. 
Results: There was greatly diminished loss of acid glycosamino- 
glycans under the treatment of CA with FU tincture in doses of 8 
mg/kg -1 and 17 mg/kg -1 compared with untreated CA. A sig- 
nificant decrease of usures, fissures, thinning of cartilage and 
total cartilage degradation was also observed. The dose of FU 17 
mg/kg -1 increased synovium fibrosis. Inflammatory infiltration of 
synovium diminished 2.4 and 4.6 times under the treatment with 
FU in doses 8 mg/kg -1 and 17 mg/kg -1 respectively. Neither the 
treatment of CA with ASA nor ethanol did result in such marked 
diminishing of inflammatory infiltration. The investigation of path- 
omorphological changes in liver and stomach showed consider- 
able effect of this agent in all treated groups. 
Conclusions: This experimental model of CA in rats may be con- 
sidered as appropriate model for studying the development of 
CA and for evaluation of the anti-inflammatory and cartilage- 
preserving activities of new agents. 
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RANDOMIZED DOUBLE-BLIND COMPARISON STUDY OF 
ROFECOXIB AND DICLOFENAC IN PATIENTS WITH 
OSTEOARTHRITIS OF THE KNEE 
P.T. Paradowski, K. Morawski K, A. Szmigiel, K. Zolynski 
Department of Orthopedics and Trauma Surge~ Military School 
of Medicine, Lodz, Poland 
Objective: The aim of the study was to compare the fficacy of 
rofecoxib, a specific inhibitor of cyclooxygenase 2 (COX-2), vs. 
diclofenac in patients with primary osteoarthritis (CA) of the knee. 
Methods: A series of 63 patients of both sexes (average 64, 
range 45 to 82 years), with painful knee osteoarthritis (according 
to ACR criteria and verified by radiographic evidence) were 
enrolled in a 6-week parallel, double-blind study. Following an 
initial screening visit, patients were randomized to receive, after a 
7-day NSAID-free washout period, either rofecoxib 12.5 mg or 
diclofenac sodium 100 mg once dally. Patients were assessed at 
weeks 2, 4 and 6, and the results were measured by the WOMAC 
osteoarthritis index (version 3.0) with use of visual analog scale 
(VAS). 
Results: Thirty-four ofecoxib and twenty-nine diclofenactreated 
patients participated in the trial. Statistically significant (p<0.01) 
improvements in all three dimensions of the WOMAC osteoarthri- 
tis index were noted in both treatment groups as compared to the 
baseline results. At the doses studied, no differences between the 
drugs in stiffness variables were observed. However, statistically 
significant differences favoring rofecoxib (p£0.05) in most of pain 
and physical function criteria were observed. Additionally, no sig- 
nificant difference between the two drugs was noted in tolerabil- 
ity. There were no serious adverse effects of the drugs during the 
trial. 
Conclusion= Specific inhibition of COX-2 by rofecoxib 12.5 mg, 
administered once daily, resulted in a clinical improvement in 
patients with CA. Rofecoxib is efficacious and well tolerated in 
patients with CA of the knee. In this group of patients it was sim- 
ilar in tolerability and superior in efficacy to diclofenac 100 
mg/day. Thus the benefit/risk ratio of rofecoxib was superior to 
that of dictofenac in this study. 
